CTNI-19. PHASE 2, MULTICENTER, RANDOMIZED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAFUSIDENIB IN PATIENTS WITH HIGH-GRADE ISOCITRATE DEHYDROGENASE 1 (IDH1)-MUTANT GLIOMA
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.0516
Abstract: Isocitrate dehydrogenase (IDH)-mutant gliomas are molecularly and clinically distinct cancers that affect primarily younger adults. Patients with World Health Organization (WHO) Grade 3 or Grade 4 IDH-mutant astrocytoma represent an unmet need because their disease… read more here.
Keywords: idh1 mutant; mutant glioma; safusidenib; phase ... See more keywords